https://scholars.lib.ntu.edu.tw/handle/123456789/637378
標題: | Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study | 作者: | Lin, Wei-Chen Tai, Wei-Chen Chang, Chung-Hsin CHIA-HUNG TU Feng, I-Che MING-JIUM SHIEH Chung, Chen-Shuan Yen, Hsu-Heng Chou, Jen-Wei Wong, Jau-Min Liu, Yu-Hwa Huang, Tien-Yu Chuang, Chiao-Hsiung Tsai, Tzung-Jiun Chiang, Feng-Fan Lu, Chien-Yu Hsu, Wen-Hung Yu, Fang-Jung Chao, Te-Hsin Wu, Deng-Chyang Ho, Ai-Sheng Lin, Hung-Hsin Feng, Chun-Lung Wu, Keng-Liang Wong, Ming-Wun CHIEN-CHIH TUNG Lin, Chun-Chi Chen, Chia-Chang Hu, Huang-Ming Lu, Lung-Sheng Wang, Huann-Sheng Wu, I-Chen Kuo, Hsin-Yu JIA-FENG WU Yao Shih, Hsiang YEN-HSUAN NI Tang, Shu-Lun Chen, Peng-Hsu SHU-CHEN WEI |
關鍵字: | Crohn’s disease; reimbursement; ulcerative colitis; vedolizumab | 公開日期: | 2-十一月-2023 | 卷: | 29 | 期: | 11 | 來源出版物: | Inflammatory bowel diseases | 摘要: | This nationwide prospective registry study investigated the real-world effectiveness, safety, and persistence of vedolizumab (VDZ) in inflammatory bowel disease (IBD) patients in Taiwan. Disease relapse rates after VDZ discontinuation due to reimbursement restriction were assessed. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/637378 | ISSN: | 1078-0998 1536-4844 |
DOI: | 10.1093/ibd/izac269 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。